Latest Advisory

  • FDA Advisory No. 2016-018 || Product Recall of Batch Specific Orlistat 120 mg Capsule (Reducin)

    FDA Advisory No. 2016-018 || Product Recall of Batch Specific Orlistat 120 mg Capsule (Reducin)

    Read more

  • FDA Advisory No. 2016-017 || Product   Recall    of    Specific   Batches   of   Co-Amoxiclav  250 mg/62.5 mg per 5mL Powder for Oral Suspension (Luvmox SF)

    FDA Advisory No. 2016-017 || Product Recall of Specific Batches of Co-Amoxiclav 250 mg/62.5 mg per 5mL Powder for Oral Suspension (Luvmox SF)

    Read more

  • FDA Advisory No. 2016-016 || Product Recall of Specific Batches of Paliperidone 6 mg Extended-Release Tablet (Invega)

    FDA Advisory No. 2016-016 || Product Recall of Specific Batches of Paliperidone 6 mg Extended-Release Tablet (Invega)

    Read more

  • FDA Advisory No. 2016-015 || Product Recall of Batch Number C30003 of Rifampicin 200 mg/5 mL Oral Suspension (Rifanid)

    FDA Advisory No. 2016-015 || Product Recall of Batch Number C30003 of Rifampicin 200 mg/5 mL Oral Suspension (Rifanid)

    Read more

  • FDA Advisory No. 2016-014 || Product Recall of Batch Specific Cefotaxime Sodium 1 g Powder for Injection (IM/IV) with brand name Haxim

    FDA Advisory No. 2016-014 || Product Recall of Batch Specific Cefotaxime Sodium 1 g Powder for Injection (IM/IV) with brand name Haxim

    Read more

Additional Instruction for Letters, Commercial Samples, and Approved Labels for Post-Marketing Surveillance (PMS) Purposes to be Submitted to the Center for Drug Regulation and Research

Consistent with the issuance of FDA Memorandum dated 14 august 2014 regarding the Receiving of Product Application and Letter, and to facilitate the processing of related services and regulatory processes, all concerned stakeholders are requested to comply with the following additional instructions:

- For letters, kindly provide contact details (e.g. telephone number(s) and/or e-mail address(es). This will allow online viewing of the letter vial DocTrack at http://www.fda.gov.ph/doctrack-status-know-the-status-of-your-application and minimize the need for the follow-up on the part of the stakeholder.

- For labels submitted as part of post-approval commitment, kindly include copies of the labeling materials as corrected by CDRR. This will facilitate the review and filling of the process of FDA.

- For commercial samples submitted as part of post-approval commitment, kindly include copies of the approved labeling material(s). This will facilitate the review and filling process of FDA.

As part of transparency and rendering faster processing of the above mentioned submissions, instead of issuing acknowledgement letters, FDA shall acknowledgement via DocTrack.

For your information and compliance

Attachments:
Download this file (announcement.pdf)announcement.pdf

 

Share Us on

Submit to FacebookSubmit to Google PlusSubmit to Twitter